These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27196668)

  • 61. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    McCann KE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 65. "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.
    Incorvaia L; Passiglia F; Rizzo S; Galvano A; Listì A; Barraco N; Maragliano R; Calò V; Natoli C; Ciaccio M; Bazan V; Russo A
    Oncotarget; 2017 Apr; 8(14):23891-23904. PubMed ID: 28055979
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
    Brönimann S; Lemberger U; Bruchbacher A; Shariat SF; Hassler MR
    Curr Opin Urol; 2020 Jul; 30(4):519-526. PubMed ID: 32427631
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
    BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.
    Liang BY; Xiong M; Ji GB; Zhang EL; Zhang ZY; Dong KS; Chen XP; Huang ZY
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):535-540. PubMed ID: 26223923
    [TBL] [Abstract][Full Text] [Related]  

  • 69. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
    BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
    Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
    [TBL] [Abstract][Full Text] [Related]  

  • 71. KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer.
    Wu Y; Chen S; Shao Y; Su Y; Li Q; Wu J; Zhu J; Wen H; Huang Y; Zheng Z; Chen X; Ju X; Huang S; Wu X; Hu Z
    Adv Sci (Weinh); 2023 Nov; 10(31):e2304638. PubMed ID: 37702443
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HDAC pharmacological inhibition promotes cell death through the eIF2α kinases PKR and GCN2.
    Peidis P; Papadakis AI; Rajesh K; Koromilas AE
    Aging (Albany NY); 2010 Oct; 2(10):669-77. PubMed ID: 21076179
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
    Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer.
    Zhu Y; Liu Z; Gui L; Yun W; Mao C; Deng R; Yao Y; Yu Q; Feng J; Ma H; Bao W
    NPJ Breast Cancer; 2023 May; 9(1):34. PubMed ID: 37156759
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
    Clarke MJ; Mulligan EA; Grogan PT; Mladek AC; Carlson BL; Schroeder MA; Curtin NJ; Lou Z; Decker PA; Wu W; Plummer ER; Sarkaria JN
    Mol Cancer Ther; 2009 Feb; 8(2):407-14. PubMed ID: 19174557
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
    Saelen MG; Ree AH; Kristian A; Fleten KG; Furre T; Hektoen HH; Flatmark K
    Radiat Oncol; 2012 Sep; 7():165. PubMed ID: 23017053
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies.
    Mehta R; Wood AC; Yu J; Kim R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):451-461. PubMed ID: 33660569
    [No Abstract]   [Full Text] [Related]  

  • 78. Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Sun X; Xu S; Li Y; Lv X; Wei M; He M
    Expert Rev Clin Pharmacol; 2023 Mar; 16(3):245-256. PubMed ID: 36908219
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
    Yamamoto KN; Hirota K; Takeda S; Haeno H
    PLoS One; 2014; 9(8):e105724. PubMed ID: 25158060
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models.
    Makvandi M; Lee H; Puentes LN; Reilly SW; Rathi KS; Weng CC; Chan HS; Hou C; Raman P; Martinez D; Xu K; Carlin SD; Greenberg RA; Pawel BR; Mach RH; Maris JM; Pryma DA
    Mol Cancer Ther; 2019 Jul; 18(7):1195-1204. PubMed ID: 31072830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.